9MW2821 clinical trials
9MW2821 is named as an intervention in 14 current clinical trials in our China register. 10 are recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is Mabwell (Shanghai) Bioscience Co., Ltd (10). The most-studied condition is Urothelial Carcinoma.
Patient leaflets for 9MW2821
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Trials by status
Trials by phase
Clinical trials of 9MW2821
14 trialsRegisters list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Conditions studied with 9MW2821
20 conditionsAll 20 conditions
| Condition (as registered) | Trials |
|---|---|
| Urothelial Carcinoma | 3 |
| Advanced Urothelial Carcinoma | 2 |
| Triple-Negative Breast Cancer | 1 |
| Urothelial Carcinoma Bladder | 1 |
| Urothelial Carcinoma Recurrent | 1 |
| Urothelial Carcinoma of the Renal Pelvis and Ureter | 1 |
| Upper Tract Urothelial Carcinoma | 1 |
| Breast Neoplasm | 1 |
| Breast Cancer | 1 |
| Breast Tumors | 1 |
| Triple-Negative Breast Cancer (TNBC) | 1 |
| Locally Advanced or Metastatic Triple-negative Breast Cancer | 1 |
| Solid Tumors | 1 |
| Advanced Breast Cancer | 1 |
| Metastatic Breast Cancer | 1 |
| Triple Negative Breast Cancer (TNBC) | 1 |
| HER2-negative Breast Cancer | 1 |
| Cervical Cancer | 1 |
| Triple-negative Breast Cancer | 1 |
| Gynecological Malignancies | 1 |
Sponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| Mabwell (Shanghai) Bioscience Co., Ltd | 10 |
| Fudan University | 2 |
| Peking University Third Hospital | 1 |
| Shanghai Junshi Bioscience Co., Ltd | 1 |
By country register
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 14 | 10 |
A trial with sites in more than one country appears in each of those registers.
Related compounds
Questions about 9MW2821 trials
How many clinical trials are testing 9MW2821?
14 current trials in our China register name 9MW2821 as a drug or biological intervention, as of the registry sync on 9 November 2026. Completed and withdrawn studies are not counted.
Are 9MW2821 trials recruiting patients?
Yes. 10 of the 14 trials are recruiting: 10 with sites in China. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors 9MW2821 clinical trials?
Mabwell (Shanghai) Bioscience Co., Ltd (10), Fudan University (2), Peking University Third Hospital (1) and Shanghai Junshi Bioscience Co., Ltd (1). The number in brackets is how many trials each organisation leads.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how 9MW2821 works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how 9MW2821 works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists 9MW2821 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 9 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.